| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
| Company Name: |
Energy Chemical |
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
CGP 78608 hydrochloride manufacturers
- CGP-78608
-
- $1980.00
-
2026-05-11
- CAS:206648-13-7
- Purity:
- Supply Ability: 10g
|
| | CGP 78608 hydrochloride Basic information |
| Product Name: | CGP 78608 hydrochloride | | Synonyms: | [(1S)-1-[[(7-BROMO-1,2,3,4-TETRAHYDRO-2,3-DIOXO-5-QUINOXALINYL)METHYL]AMINO]ETHYL]PHOSPHONIC ACID HYDROCHLORIDE;((1S)-1-(((7-Bromo-1,2,3,4-tetrahydro-2,3-dioxo-5-quinoxalinyl)methyl)amino)ethyl]phosphonicacidhydrochloride;CGP78608HCl;Phosphonic acid, P-[(1S)-1-[[(7-bromo-1,2,3,4-tetrahydro-2,3-dioxo-5-quinoxalinyl)methyl]amino]ethyl]-;CGP 78608 hydrochlor;CGP 78608 hydrochloride | | CAS: | 206648-13-7 | | MF: | C11H13BrN3O5P | | MW: | 378.12 | | EINECS: | | | Product Categories: | | | Mol File: | 206648-13-7.mol |  |
| | CGP 78608 hydrochloride Chemical Properties |
| density | 1.757±0.06 g/cm3(Predicted) | | storage temp. | Store at RT | | solubility | <41.46mg/ml in 2.2eq. NaOH | | pka | 0.66±0.10(Predicted) |
| | CGP 78608 hydrochloride Usage And Synthesis |
| Uses | CGP 78608 is a potent and selective NMDA antagonist. | | Definition | ChEBI: CGP 78608 is a phosphonic acid in which the hydrogen attached to phosphorous is substituted by a 1-{[(7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)methyl]amino}ethyl group. Potent and selective NMDA antagonist that acts through the glycine site (IC50 = 5 nM). Displays >500-fold selectivity over kainate and AMPA receptors (IC50 values are 2.7 and 3 muM respectively). Anticonvulsant in vivo following systemic administration. It has a role as a NMDA receptor antagonist and an anticonvulsant. It is a quinoxaline derivative, an organobromine compound, a secondary amino compound and a member of phosphonic acids. It contains a CGP 78608(1+). | | Biological Activity | Potent and selective NMDA antagonist that acts through the glycine site (IC 50 = 5 nM). Displays > 500-fold selectivity over kainate and AMPA receptors (IC 50 values are 2.7 and 3 μ M respectively). Anticonvulsant in vivo following systemic administration. Also available as part of the NMDA Receptor - Glycine Site Tocriset™ . | | in vivo | CGP-78608 displays potent anticonvulsant effects after i.p. administration in the electroshock-induced convulsions assay in mice[1]. |
| | CGP 78608 hydrochloride Preparation Products And Raw materials |
|